SALT LAKE CITY , Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA ), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2024 ended September 30, 2024 .
Recent Highlights: Data analysis for full Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study underway after database was locked in September and now seeking publication of results in connection with key pregnancy and maternal health conferences in early 2025 and manuscript submission to a quality peer-reviewed journal. Awareness campaign activated with TV programs by Viewpoint with Dennis Quaid and Empowered with Meg Ryan . These programs are expected to be distributed to public television stations in all 50 states, and in over 84 million homes via MSNBC, CNBC, CNN or similar networks broadly supporting Sera's goal of informing the public about our test-and-treat offering and how it can support improved pregnancy outcomes.
Beginning October 1, 2024 , and as featured in a Time Magazine article , began enabling access to PreTRM® testing through the Company's website, with home sample collection. The expectant mother then will receive the results for discussion with her physician. This new capability is expected to drive consumer-initiated sales supported by the awareness campaign.
To provide e.
